Abstract:Atherosclerosis research typically focuses on the evolution of intermediate or advanced atherosclerotic lesions rather than on prelesional stages of atherogenesis. Yet these early events may provide decisive leads on the triggers of the pathologic process, before lesions become clinically overt. Thereby, it is mandatory to consider extracellular lipoprotein deposition at this stage as the prerequisite of foam cell formation leading to a remarkable accumulation of LDL (Low Density Lipoproteins). As progression of atherosclerosis displays the characteristic features of a chronic inflammatory process on the one hand and native LDL lacks inflammatory properties on the other hand, the lipoprotein must undergo biochemical modification to become atherogenic. During the last 25 years, evidence was accumulated in support of a different concept on atherogenesis proposing that modification of native LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or eLDL) rather than oxidation and contending that the physiological events leading to macrophage uptake and reverse transport of eLDL first occur without inflammation (initiation with reversion). Preventing or reversing initial atherosclerotic lesions would avoid the later stages and therefore prevent clinical manifestations. This concept is in accordance with the response to retention hypothesis directly supporting the strategy of lowering plasma levels of atherogenic lipoproteins as the most successful therapy for atherosclerosis and its sequelae. Apart from but unquestionable closely related to this concept, there are several other hypotheses on atherosclerotic lesion initiation favoring an initiating role of the immune system ('vascular-associated lymphoid tissue' (VALT)), defining foam cell formation as a variant of lysosomal storage disease, relating to the concept of the inflammasome with crystalline cholesterol and/or mitochondrial DAMPs (damage-associated molecular patterns) being mandatory in driving arterial inflammation and, last but not least, pointing to miRNAs (micro RNAs) as pivotal players. However, direct anti-inflammatory therapies may prove successful as adjuvant components but will likely never be used in the absence of strategies to lower plasma levels of atherogenic lipoproteins, the key point of the perception that atherosclerosis is not simply an inevitable result of senescence. In particular, given the importance of chemical modifications for lipoprotein atherogenicity, regulation of the enzymes involved might be a tempting target for pharmacological research.

Targeting Foam Cell Formation In Atherosclerosis: Therapeutic Potential Of Natural Products

Foam Cells: The Origin of Formation and Target for Plant-derived Bioactive Compounds

Lipid-laden Foam Cells in the Pathology of Atherosclerosis: Shedding Light on New Therapeutic Targets

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

Bioactive components to inhibit foam cell formation in atherosclerosis

Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis

Lipid Homeostasis and the Formation of Macrophage-Derived Foam Cells in Atherosclerosis

Foam Cells in Atherosclerosis: Novel Insights into Its Origins, Consequences, and Molecular Mechanisms.

An in vitro model of foam cell formation induced by a stretchable microfluidic device

Natural products: potential therapeutic agents for atherosclerosis

The Cell Origins of Foam Cell and Lipid Metabolism Regulated by Mechanical Stress in Atherosclerosis

Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis

A New Therapeutic End for Atherosclerotic Cardiovascular Disease

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

Cell adhesion molecule-mediated therapeutic strategies in atherosclerosis: From a biological basis and molecular mechanism to drug delivery nanosystems

Pathways of smooth muscle foam cell formation in atherosclerosis

Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy

Smooth Muscle Cell—Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location

Macrophages and Foam Cells: Brief Overview of Their Role, Linkage, and Targeting Potential in Atherosclerosis

Lipid droplet-associated proteins in atherosclerosis (Review)

CD47-SIRPα signaling-inspired engineered monocytes for preventing the progression of atherosclerotic plaques